Guardian Pharmacy Services, Inc. (GRDN) Price Target Analysis
Updated Jun 26, 2026
Analyst Rating: Buy
Based on 4 analysts1.4% Below Target
GRDN trades 1.4% below Wall Street's consensus target of $41.00.
Current Price$40.44
Average Target$41.00
Target
Current
Low$36.00
Median$40.00
High$47.00
Analyst Target Range
Forward P/E32.1x
(Growth Premium)
PEG Ratio1.71
(Fair)
Implied Growth+51.2%
(High Growth)
Analyst Spread26.8%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes GRDN achieves its forward estimates and maintains a stable P/E multiple of 32.1x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
GRDN Price Target Analysis
Updated June 30, 2026As of June 30, 2026, Guardian Pharmacy Services, Inc. (GRDN) has a Wall Street consensus price target of $41.00, based on estimates from 4 covering analysts. With the stock currently trading at $40.44, this represents a potential upside of +1.4%. The company has a market capitalization of $2.56B.
Analyst price targets range from a low of $36.00 to a high of $47.00, representing a 27% spread in expectations. The median target of $40.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GRDN trades at a trailing P/E of 51.8x and forward P/E of 32.1x. The forward PEG ratio of 1.71 indicates reasonable valuation for growth. Analysts expect EPS to grow +51.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $32.86, with bear and bull scenarios of $20.70 and $43.29 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+19.8%
Industry Consensus
Avg Forward P/E
30.5x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 OMCLOmnicell, Inc. | $1.9B | $40.92 | $57.20 | +39.8% | Hold | 21.1x | 19 |
 PINCPremier, Inc. | $2.3B | $28.26 | $33.15 | +17.3% | Hold | 20.8x | 31 |
 CVSCVS Health Corporation | $132.2B | $103.58 | $103.64 | +0.1% | Buy | 14.0x | 41 |
 CCRNCross Country Healthcare, Inc. | $427M | $13.21 | $12.50 | -5.4% | Hold | 142.8x | 14 |
 MCKMcKesson Corporation | $89.9B | $747.53 | $994.86 | +33.1% | Buy | 16.9x | 31 |
 CAHCardinal Health, Inc. | $55.6B | $236.22 | $253.38 | +7.3% | Buy | 21.9x | 33 |
 VEEVVeeva Systems Inc. | $28.6B | $176.16 | $235.38 | +33.6% | Buy | 19.4x | 43 |
 ENSGThe Ensign Group, Inc. | $9.2B | $158.19 | $222.33 | +40.5% | Buy | 20.9x | 13 |
 SEMSelect Medical Holdings Corporation | $2.1B | $16.53 | $17.75 | +7.4% | Hold | 13.5x | 14 |
 ADUSAddus HomeCare Corporation | $1.8B | $98.05 | $122.00 | +24.4% | Buy | 14.0x | 16 |
GRDN — Frequently Asked Questions
Quick answers to the most common questions about buying GRDN stock.
What is the GRDN stock price target for 2026?
The consensus price target for GRDN is $41, close to the current price of $40.44 (1.4% implied move). Based on 4 analyst estimates, the stock appears fairly valued near current levels.
Is GRDN a buy, sell, or hold?
GRDN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $41 implies 1.4% upside from current levels.
Is GRDN stock overvalued or undervalued?
GRDN trades at a forward P/E of 32.0952x, representing a moderate valuation. With analysts targeting $41 (1.4% implied move), the stock appears close to fair value.
How high can GRDN stock go?
The most bullish Wall Street analyst has a price target of $47 for GRDN, while the most conservative target is $36. The consensus of $41 represents the median expectation. Our quantitative valuation model projects a bull case target of $43 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover GRDN stock?
GRDN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GRDN stock forecast?
The 12-month GRDN stock forecast based on 4 Wall Street analysts shows a consensus price target of $41, with estimates ranging from $36 (bear case) to $47 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $33, with bear/bull scenarios of $21/$43.
What is GRDN's fair value based on fundamentals?
Our quantitative valuation model calculates GRDN's fair value at $33 (base case), with a bear case of $21 and bull case of $43. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.
What is GRDN's forward P/E ratio?
GRDN trades at a forward P/E ratio of 32.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 51.8x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy GRDN stock?
GRDN appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $41 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GRDN price targets vary so much?
GRDN analyst price targets range from $36 to $47, a 27% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $41 consensus represents the middle ground. Our model's $21-$43 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare